Tag archive for ‘VITALITY-ALS trial fails’
Cytokinetics: VITALITY-ALS Trial Fails (CYTK, Buy, $8.00)
CYTK announced today that the VITALITY-ALS trial in ALS failed which is obviously a significant disappointment. The stock is trading down to $8.00 in pre-market trading. I had thought that there was a good chance for success in the trial, but recognized that ALS is a tough disease in which there have been innumerable drug […]